Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.48 |
| ▸ | SCD | O00767 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17153735 | 0.96 | PTGS2 (0.50) | PTGS2NR1H2NR1H3SCDKCNH2 | |
| SCHEMBL6243674 | 0.93 | KCNH2 (0.50) | PTGS2NR1H2NR1H3KCNH2LOXL2 | |
| SCHEMBL8770634 | 0.85 | PTGS2 (0.68) | PTGS2 | |
| SCHEMBL26807210 | 0.85 | PTGS2 (0.41) | PTGS2NR1H2NR1H3SCDKCNH2 | |
| SCHEMBL145847 | 0.84 | NR1H2 (0.45) | NR1H2NR1H3KCNH2LOXL2RXRA | |
| SCHEMBL5831675 | 0.84 | PTGS2 (0.56) | PTGS2NR1H2NR1H3SCD | |
| SCHEMBL14320650 | 0.84 | CA12 (0.51) | NR1H2NR1H3KCNH2LOXL2 | |
| SCHEMBL8770103 | 0.84 | KCNH2 (0.49) | PTGS2NR1H2NR1H3KCNH2LOXL2 | |
| SCHEMBL30690007 | 0.84 | ALOX5 (0.53) | NR1H2NR1H3SCDKCNH2LOXL2 | |
| SCHEMBL17367960 | 0.84 | ALOX5 (0.53) | NR1H2NR1H3SCDKCNH2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113631548-B | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-108017479-B | Method for producing aromatic compound | 东曹株式会社 | 2022-07-29 | — | — | CN | disclosed |
| CN-113631548-A | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2021-11-09 | — | — | CN | disclosed |
| US-10246393-B2 | Method for producing aromatic compound | TOSOH CORPORATION (JP) | 2019-04-02 | — | — | US | disclosed |
| US-20180118646-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | TOSOH CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180118646-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | TOSOH CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3315486-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | Tosoh Corporation (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-8476225-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8242278-B2 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20050096471-A1 | Process for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1473286-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-4878938-A | PRE- AND POSTEMERGENCE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
| US-4764204-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-08-16 | — | — | US | disclosed |
| US-4705556-A | PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | PTGS2 861/4885NR1H2 3194/4885NR1H3 3202/4885 |
| US-20180118646-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND | HAO2, PAH, TYR | PTGS2 3659/4885NR1H2 4574/4885NR1H3 4326/4885 |
| US-10246393-B2 | Method for producing aromatic compound | HAO2, PAH, TYR | PTGS2 3659/4885NR1H2 4574/4885NR1H3 4326/4885 |
| US-20050096471-A1 | Process for producing biaryl compound | PPOX, CAT, TYR | PTGS2 830/4885NR1H2 1482/4885NR1H3 1907/4885 |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | NFKBIA, IKBKB, IDO2 | PTGS2 35/4885NR1H2 700/4885NR1H3 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.